查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1444175

糖生物學：市場佔有率分析、產業趨勢與統計、成長預測（2024-2029）

Glycobiology - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)
出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

糖生物學市場規模預計到 2024 年為 6.2 億美元，預計到 2029 年將達到 12.4 億美元，在預測期內（2024-2029 年）成長至 148.7 億美元，年複合成長率為 %。

糖生物學市場

與 COVID-19 相關的一些疫苗開發工作主要集中在冠狀病毒跨膜刺突 (S) 糖蛋白上，該糖蛋白從病毒表面延伸並介導進入宿主細胞。病毒和宿主細胞之間這種串擾的關鍵步驟是 S 糖蛋白與人類細胞表面的 ACE2 受體的結合。已知 S-糖蛋白和 ACE2 受體均被廣泛糖基化。也就是說，它們含有複雜的共用連接寡糖，稱為聚醣。這為疫情期間聚醣的研究開闢了一條有希望的途徑。許多研究證明聚醣在 COVID-19感染疾病中很重要。 RIKEN 計算科學中心 (R-CCS) 的研究人員在 2021 年 3 月進行的一項研究發現，當病毒允許 COVID-19 進入人體細胞時，聚醣分子在結構變化中發揮重要作用。 。

根據 2021 年 6 月發表在《分子生物學雜誌》上的一項研究，碳水化合物結合蛋白質參與人類防禦和病毒感染能力。用於預防和治療 COVID-19 的藥物包括聚醣抗原、抗聚醣抗體、聚醣結合蛋白質、凝集素抑制劑、多醣、糖苷酶抑制劑和糖苷。因此，上述因素顯示全球糖生物學市場受到了COVID-19感染疾病大流行的顯著影響。然而，市場目前正在恢復疫情前的狀態，預計在預測期內將出現健康成長。

糖生物學市場成長的主要因素是關於分析醣組、聚醣和蛋白質組的新興技術的研究和開發活動的增加。聚醣通常存在於細胞表面，在人體系統中扮演重要角色。它們是許多遺傳疾病的病因，在癌症的發展中也扮演著重要角色。 2021年12月，澳洲格里菲斯大學格氏研究所獲得澳洲癌症研究基金會（ACRF）180萬美元津貼，成立ACRF國際癌症格氏中心。 2022 年 8 月，以亞伯達大學為中心的泛加拿大卓越中心網路 GlycoNet 將成為加拿大創新基金會專業，繼續其研究醣體學以造福人類健康的使命。它獲得了美國的投資來自科學舉措基金的1068 萬美元。

因此，由於上述因素，預計所研究的市場在預測期內將出現強勁成長。

糖生物學市場趨勢

藥物發現和開發預計將成為最大的成長領域

隨著慢性病負擔的增加，開發新藥的需求也隨之增加。聚醣在細胞間相互作用等生物過程中發揮重要作用，因此在藥物開發中具有重要意義。因此，藥物是透過修飾糖鏈來合成的。例如，透明質酸（一種天然存在的Glico單元）在醫學上具有廣泛的用途。它用於術後傷口，對於治療骨關節炎至關重要。

根據 2021 年 7 月發表在《國際奈米醫學雜誌》上的一項研究，聚醣奈米結構被認為是分子診斷、抗病毒治療方法和疫苗開發的潛在標靶。在奈米尺度上研究聚醣可以開發疫苗、藥物傳遞系統以及針對病毒和感染疾病的生物分子療法。可以使用糖蛋白表達系統和基因工程工具來創建基於聚醣的自身佐劑疫苗，以改善免疫抗原性和疫苗反應。因此，糖生物學在疫苗開發中發揮著重要作用，從而促進了該領域的發展。 2022 年 2 月，水穀糖科學基金會收到了 28 個國家的 119 份研究津貼申請。經過仔細評估科學和社會價值、潛力和可行性後，基金會決定向 14 個計劃提供約 51 萬美元的津貼。因此，預計津貼和核准將促進糖生物學的研究和開發，從而加速該領域的發展。

預計北美將在預測期內主導市場

除了美國慢性病負擔日益加重之外，研發活動和政府資助計畫的增加預計將為北美地區創造更多機會。 美國9 月，科學書籍、雜誌和電子媒體出版商冷泉港實驗室出版社（CSHL Press）宣布成立一個新計畫。 InterVenn Biosciences 是一家利用Glico改變醫療保健未來的臨床技術公司，參與支持向 CSHL Press 提供的津貼。這表明美國對糖生物學的日益關注，預計將推動未來幾年的市場成長。

Vector Laboratories 是創新蛋白質體學和糖生物學解決方案的先驅，於 2022 年 3 月在加州紐瓦克開設了一家新工廠。這些螢光(IF)套件能夠對生物系統中的複雜聚醣進行分析和表徵，並且完全整合用於檢測組織切片中的聚醣表達。隨著越來越多的研究人員表示對研究糖生物學的興趣，糖生物學繼續受歡迎，因為它有可能影響腫瘤學等疾病研究的重要領域。Masu。因此，由於上述因素，預計所研究的市場在預測期內將出現強勁成長。

糖生物學產業概述

糖生物學市場競爭適中，有大量公司為市場成長做出了重大貢獻。新產品發布、併購、夥伴關係和合作是這些公司實現永續成長的關鍵策略。市場的主要企業包括安捷倫科技公司、沃特世公司、島津公司、默克公司和新英格蘭生物實驗室。

其他福利

  • Excel 格式的市場預測 (ME) 表
  • 3 個月分析師支持

目錄

第1章 簡介

  • 研究假設和市場定義
  • 調查範圍

第2章調查方法

第3章執行摘要

第4章市場動態

  • 市場概況
  • 市場促進因素
    • 增加政府和私人對糖組學和蛋白​​質組學研究的資助
    • 製藥和生技公司的研發支出增加
  • 市場限制因素
    • 產品高成本
    • 缺乏熟練的專業人員
  • 波特五力分析
    • 新進入者的威脅
    • 買方議價能力
    • 供應商的議價能力
    • 替代產品的威脅
    • 競爭公司之間的敵意強度

第5章市場區隔

  • 依產品
    • 酵素
    • 裝置
    • 套件和試劑
  • 按用途
    • 診斷
    • 藥物發現與開發
    • 腫瘤學
    • 免疫學
    • 其他用途
  • 按最終用戶
    • 製藥和生物技術公司
    • 合約研究組織
    • 其他最終用戶
  • 地區
    • 北美洲
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 義大利
      • 西班牙
      • 其他歐洲國家
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳洲
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • GCC
      • 南非
      • 其他中東和非洲
    • 南美洲
      • 巴西
      • 阿根廷
      • 南美洲其他地區

第6章 競爭形勢

  • 公司簡介
    • Agilent Technologies
    • Bruker Corporation
    • Danaher Corporation
    • Merck KGaA
    • New England Biolabs
    • ProZyme
    • Shimadzu Corporation
    • Takara Bio
    • Thermo Fisher Scientific
    • Waters Corporation

第7章市場機會與未來趨勢

簡介目錄
Product Code: 53251

The Glycobiology Market size is estimated at USD 0.62 billion in 2024, and is expected to reach USD 1.24 billion by 2029, growing at a CAGR of 14.87% during the forecast period (2024-2029).

Glycobiology - Market

Several vaccine development efforts related to COVID-19 primarily focused on the coronavirus transmembrane spike (S) glycoprotein, which extends from the viral surface and mediates host cell entry. A critical step in this crosstalk between the virus and the host cell is the binding of S-glycoprotein to the ACE2 receptor on the surface of human cells. Both S-glycoprotein and ACE2 receptors are known to be extensively glycosylated, i.e., they contain covalently linked complex oligosaccharides called glycans. This makes a promising research path on glycans during the pandemic. Many research studies proved that glycans are crucial in COVID-19 infection. A March 2021 research study by researchers at RIKEN Center for Computational Science (R-CCS) found that glycans sugar molecules play an essential role in the structural changes that occur when the virus causes COVID-19 to invade human cells.

According to a study published in the Journal of Molecular Biology in June 2021, glycan-binding proteins are involved in both human defense and the ability of viruses to infect. Drugs that should be considered for COVID-19 prevention and treatment include glycan antigens, anti-glycan antibodies, glycan-binding proteins, lectin inhibitors, polysaccharides, glycosidase inhibitors, and glycosides. Thus, the above-mentioned factors state that the global glycobiology market was significantly impacted by the COVID-19 pandemic. However, the market is currently gaining its pre-pandemic nature and is expected to witness healthy growth over the forecast period.

The major factor responsible for the growth of the glycobiology market is the increasing research and development activities about glycomes and emerging technology for analyzing glycans and proteomes. Glycans, generally present on the cell surface, play a crucial role in the body system. They are responsible for many hereditary diseases and have a vital role in cancer development. In December 2021, Griffith University's Institute for Glycomics of Australia received a grant of USD 1.80 million from the Australian Cancer Research Foundation (ACRF) to establish the ACRF International Centre for Cancer Glycomics. In August 2022, GlycoNet, a pan-Canadian network of Centers of Excellence centered at UAlberta, received a USD 10.68 million investment from the Canadian Foundation for Innovation's Major Science Initiative Fund to continue its mission of researching glycomics for the benefit of human health.

Thus, owing to the above-mentioned factors, the market studied is believed to witness strong growth over the forecast period.

Glycobiology Market Trends

Drug Discovery and Development is Expected to be the Largest Growing Segment

As the burden of chronic diseases increases, the need to develop new drugs is also increasing. Glycans play a key role in biological processes, such as cell-cell interaction, and thus have immense importance in drug development. Therefore, glycan chains are modified to synthesize drugs. For instance, hyaluronan, a naturally occurring disaccharide unit of glycosaminoglycan, has wide applications in medicine. It is used in post-surgical wounds and is essential in osteoarthritis treatment.

According to a study published in the International Journal of Nanomedicine in July 2021, glycan nanostructures are thought to be potential targets for molecular diagnosis, antiviral therapeutics, and vaccine development. The development of vaccines, drug delivery systems, and biomolecular therapeutics for viruses and infectious diseases can be enabled by studying glycans at the nanoscale. Glycan-based self-adjuvanted vaccines can be created to improve immunogenicity and vaccine response using glycoprotein expression systems and genetic engineering tools. Thus, glycobiology plays an essential role in the development of vaccines, thereby boosting the growth of the segment. In February 2022, Mizutani Foundation for Glycoscience received 119 research grant applications from 28 countries. After careful evaluation of scientific and social merit, potentiality, and feasibility, the Foundation decided to award grants of approximately USD 0.51 million to 14 projects. Thus, grants and approvals are expected to boost research and development in glycobiology, thereby boosting the growth of the segment.

North America is Expected to Dominate the Market Over the Forecast Period

The increasing research and development activities and government funding programs, along with the growing burden of chronic diseases in the United States, are expected to create more opportunities for the North America region. In September 2022, Cold Spring Harbor Laboratory Press (CSHL Press), a publisher of scientific books, journals, and electronic media established a new program to provide access to the field of glycobiology, which is developing rapidly across the United States. InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, is involved in supporting the grant for CSHL Press. This indicates the increasing focus on glycobiology which is expected to fuel the market growth in coming years across the United States.

In March 2022, Vector Laboratories, the pioneer of innovative proteomic and glycobiology solutions, opened its new facility in Newark, California. These immunofluorescence (IF) kits enable the profiling and characterization of complex glycans in biological systems and are completely integrated for the detection of glycan expression in tissue sections. As more researchers express interest in studying glycobiology due to the potential impact it may have on important areas of illness research like oncology, glycan research is continuing to gain popularity. Hence, owing to the above-mentioned factors, the market studied is expected to witness strong growth over the forecast period.

Glycobiology Industry Overview

The glycobiology market is moderately competitive, with the presence of a considerable number of companies that significantly contribute to the market growth. New product launches, mergers and acquisitions, partnerships, and collaborations are the key strategies adopted by these companies for sustainable growth. Some key companies in the market include Agilent Technologies, Waters Corporation, Shimadzu Corporation, Merck KGaA, and New England Biolabs, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Government and Private Funding for Glycomics and Proteomics Research
    • 4.2.2 Growing R&D Expenditures by Pharmaceutical and Biotechnology Companies
  • 4.3 Market Restraints
    • 4.3.1 High Product Cost
    • 4.3.2 Low Availability of Skilled Professionals
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size - Value in USD million)

  • 5.1 By Product
    • 5.1.1 Enzymes
    • 5.1.2 Instruments
    • 5.1.3 Kits and Reagents
  • 5.2 By Application
    • 5.2.1 Diagnostics
    • 5.2.2 Drug Discovery and Development
    • 5.2.3 Oncology
    • 5.2.4 Immunology
    • 5.2.5 Other Applications
  • 5.3 By End User
    • 5.3.1 Pharmaceutical and Biotechnology Companies
    • 5.3.2 Contract Research Organizations
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies
    • 6.1.2 Bruker Corporation
    • 6.1.3 Danaher Corporation
    • 6.1.4 Merck KGaA
    • 6.1.5 New England Biolabs
    • 6.1.6 ProZyme
    • 6.1.7 Shimadzu Corporation
    • 6.1.8 Takara Bio
    • 6.1.9 Thermo Fisher Scientific
    • 6.1.10 Waters Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS